|
|
|
| home > pmps > autumn 2003 > future cold chain technology for the 21st century: the 'blue sky' idea |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Cold chain distribution in relation to the pharmaceutical and biotech industry has often been perceived as the less glamorous and 'latent' service that is allied to this business sector. However, the importance of ensuring that a temperature-sensitive medicinal product reaches the end-user without compromising integrity and efficacy is paramount. It is therefore not strange that awareness, comprehension and advances are continually on the increase due to the pro-active actions of service providers, that is, manufacturers of designed insulated shipping systems and part/fully active shipping systems. Although reaction is based on fulfilling more stringent customer requirements to design solutions that can withstand the most extreme of conditions, there are other contributing, key factors that have come into the spotlight over recent years which are promoting industry response.
Firstly, according to the Biotechnology Industry Organisation 2002, there are currently 350 biotech products and vaccines at various phases within the clinical trials process, and a large proportion are considered to be temperature-sensitive. It is estimated that the growth of such products is in the region of 15 per cent per year.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Etihad Cargo Achieves IATA CEIV Pharma Recertification for Pharmaceutical Logistics
Abu Dhabi, United Arab Emirates – Etihad Cargo, the cargo and
logistics arm of Etihad Aviation Group, has been awarded Center of
Excellence for Independent Validators (CEIV) Pharma recertification by
the International Air Transport Association (IATA). The carrier is one
of only 37 airlines to hold IATA CEIV Pharma certification globally.
More info >> |
|
 |
White Papers |
 |
|
pAVEway™ expression system for the efficient expression of therapeutic proteins
Fujifilm Diosynth Biotechnologies
One of the major bottlenecks in the production of biopharmaceuticals is
the efficient expression of therapeutic proteins in microbial or
mammalian cells. The Escherichia coli pAVEway™ expression system
described here has been developed to ensure high product titres and
efficient scale up to GMP manufacture, whilst minimising many common
issues seen in other expression systems, such as ‘leaky’ expression
(expression of recombinant protein in the absence of inducer).
More info >> |
|
|
